On July 29, 2021, Financing China released the results of the "2020-2021 Industrial King" ranking. As the first half of the "14th Five-Year Plan" comes to an end, China's domestic gross domestic product (GDP) exceeded 53 trillion yuan in the first half of 2021, showing a year-on-year growth of 12.7%. The country is steadily progressing on the path of recovery.

Against this backdrop, Financing China conducted the selection of the "2020-2021 China New Economy Enterprise List" by identifying leaders and innovators in various fields. The list covers multiple sectors, including consumer goods, green industries, internet applications, enterprise services, semiconductors and integrated circuits, and new-generation information technology. Keythera Biopharmaceuticals made it to the TOP 50 list of high-growth enterprises in China's new economy, demonstrating recognition from professional evaluation institutions once again, following their previous inclusion in the 2020 Venture50 list. Keythera Biopharmaceuticals aims to continue its dedication to innovative drug development in this favorable environment, striving for growth, becoming an outstanding player in the biopharmaceutical industry, advancing new drug launches, and benefiting more patients.

Back to List